NTIDs with high variability [Design Issues]

posted by ioanam – Romania, 2010-06-07 15:52 (5868 d 10:11 ago) – Posting: # 5452
Views: 12,184

Which is the most appropriate design for a narrow therapeutic index drug with very high intra-subject variability?

For example, we have an immunosuppressive agent with an intra-subject CV% > 45%.
Using a standard two – way crossover design with acceptance interval tightened (90.00 – 111.11%), we will have a sample size of more than 300 subjects :-(.

It is possible to use a replicate design in this situation?

Thank you,
Jo

Complete thread:

UA Flag
Activity
 Admin contact
23,656 posts in 4,994 threads, 1,570 registered users;
249 visitors (0 registered, 249 guests [including 34 identified bots]).
Forum time: 02:04 CEST (Europe/Vienna)

When you meet the Buddha, you kill him;
when you meet the patriarchs, you kill them.    Wumen Huikai

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5